Efficacy of recombinant factor VIIa administered by continuous infusion to haemophilia patients with inhibitors.
We have prospectively monitored treatment of haemophilia patients with inhibitors by recombinant factor VIIa (rFVIIa) administered by continuous infusion to obtain more insight in the underlying factors of the clinical efficacy of this administration method. At present, 43 treatment episodes of 14 different Dutch haemophilia inhibitor patients are included in the database. Analysis of the data showed a discrepancy between the efficacy of rFVIIa continuous infusion treatment of acute and surgical bleeds in the oral cavity [one (14%) effective, two (29%) partially effective, four (57%) not effective] and other parts of the body [29 (80%) effective, four (11%) partially effective, two (6%) not effective, one (3%) impossible to classify]. Patients who had acute or surgical oral cavity bleeds, uncontrolled by rFVIIa continuous infusion, reacted favourably to rFVIIa continuous infusion in other locations of the body. Acute bleeding episodes in the oral cavity, which could not be controlled by rFVIIa continuous infusion, stopped when the treatment regimen was switched to rFVIIa bolus injections. Finally, haemostatic control during dental extractions was excellent after the initial rFVIIa bolus injection preceding the continuous infusion, but rebleeds occurred in all patients within 48 h under rFVIIa continuous infusion coverage. These observations suggest that the efficacy of rFVIIa continuous infusion depends, at least in part, on the location of the body in which the bleeding occurs and that rFVIIa bolus injections are more effective than rFVIIa continuous infusion in the oral cavity. We hypothesize that the inability of rFVIIa continuous infusion treatment to sufficiently inhibit fibrinolysis is the underlying cause of the decreased efficacy of rFVIIa continuous infusion treatment in the oral cavity.
Van Creveldkliniek, University Medical Centre Utrecht, The Netherlands. e.mauserbunschoten@digd.azu.nl
E P
EP
Mauser-Bunschoten
M M W
MM
Koopman
A D E
AD
Goede-Bolder
F W G
FW
Leebeek
J
J
van der Meer
G M
GM
van Marwijk Kooij
P W G
PW
van der Linden
D000208:Acute Disease; D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000378:metabolism; D019774:Blood Coagulation Factor Inhibitors / Q000378:metabolism; D002648:Child; D016208:Databases, Factual; D005167:Factor VII / Q000008:administration & dosage* / Q000627:therapeutic use; D015942:Factor VIIa; D005260:Female; D006467:Hemophilia A / Q000188:drug therapy* / Q000276:immunology; D002836:Hemophilia B / Q000188:drug therapy / Q000276:immunology; D006488:Hemostasis, Surgical / Q000379:methods*; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009426:Netherlands; D006472:Oral Hemorrhage / Q000188:drug therapy; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000627:therapeutic use
D001323:Autoantibodies; D019774:Blood Coagulation Factor Inhibitors; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa